1. Home
  2. ATNM vs SHLT Comparison

ATNM vs SHLT Comparison

Compare ATNM & SHLT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • ATNM
  • SHLT
  • Stock Information
  • Founded
  • ATNM 2000
  • SHLT 1987
  • Country
  • ATNM United States
  • SHLT Israel
  • Employees
  • ATNM N/A
  • SHLT N/A
  • Industry
  • ATNM Biotechnology: Pharmaceutical Preparations
  • SHLT Business Services
  • Sector
  • ATNM Health Care
  • SHLT Consumer Discretionary
  • Exchange
  • ATNM Nasdaq
  • SHLT Nasdaq
  • Market Cap
  • ATNM 56.5M
  • SHLT 63.6M
  • IPO Year
  • ATNM N/A
  • SHLT N/A
  • Fundamental
  • Price
  • ATNM $1.73
  • SHLT $2.75
  • Analyst Decision
  • ATNM Strong Buy
  • SHLT Strong Buy
  • Analyst Count
  • ATNM 5
  • SHLT 1
  • Target Price
  • ATNM $14.20
  • SHLT $11.00
  • AVG Volume (30 Days)
  • ATNM 285.8K
  • SHLT 4.2K
  • Earning Date
  • ATNM 10-31-2024
  • SHLT 09-26-2024
  • Dividend Yield
  • ATNM N/A
  • SHLT N/A
  • EPS Growth
  • ATNM N/A
  • SHLT N/A
  • EPS
  • ATNM N/A
  • SHLT N/A
  • Revenue
  • ATNM $81,000.00
  • SHLT $55,939,000.00
  • Revenue This Year
  • ATNM $186.10
  • SHLT N/A
  • Revenue Next Year
  • ATNM $19,248.94
  • SHLT N/A
  • P/E Ratio
  • ATNM N/A
  • SHLT N/A
  • Revenue Growth
  • ATNM 80.00
  • SHLT N/A
  • 52 Week Low
  • ATNM $1.33
  • SHLT $2.60
  • 52 Week High
  • ATNM $10.24
  • SHLT $11.20
  • Technical
  • Relative Strength Index (RSI)
  • ATNM 41.48
  • SHLT 33.11
  • Support Level
  • ATNM $1.48
  • SHLT $2.60
  • Resistance Level
  • ATNM $1.80
  • SHLT $2.91
  • Average True Range (ATR)
  • ATNM 0.12
  • SHLT 0.17
  • MACD
  • ATNM 0.04
  • SHLT -0.03
  • Stochastic Oscillator
  • ATNM 54.44
  • SHLT 15.63

About ATNM Actinium Pharmaceuticals Inc. (Delaware)

Actinium Pharmaceuticals Inc is a biopharmaceutical company engaged in the development of radiotherapies for patients with cancers lacking effective treatment options. The company's proprietary technology platform utilizes monoclonal antibodies to deliver radioisotopes directly to cells of interest to kill those cells safely and effectively. Its product candidates are Iomab-B, an antibody-drug construct containing iodine 131 (I-131), used for hematopoietic stem cells transplantation in various indications and Actimab-A, an antibody-drug construct containing actinium 225 (Ac-225), currently in human clinical trials for acute myeloid leukemia.

About SHLT SHL Telemedicine Ltd

SHL Telemedicine Ltd develops and markets personal telemedicine solutions. It consists of the transmission of medical data by an individual, from a remote location to a medical call center through telecommunication networks. The company offers solutions to subscribing patients, health insurance companies, hospitals, clinics, and physicians. It provides healthcare professional solutions to patients suffering from congestive heart failure, chronic obstructive pulmonary disease, and readmission solutions for reducing heart-related readmissions. In addition, consumer solutions include cardiac monitoring services. The company's geographical segments Israel, Europe, and the rest of the world, out of which majority revenue comes from Israel.

Share on Social Networks: